Imagine a world where 3D bioprinting can be utilized to replace damaged and nonfunctioning hearts. Where long donor waitlists and the fear of organ rejection are eliminated by creating a fully functioning heart using the patient’s own cells. That world is today.
In this month’s spotlight, The Hechtman Group is pleased to feature BIOLIFE4D.
BIOLIFE4D is a pioneering biotech company laser-focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. “We are a company with a truly important objective,” discusses CEO Steven Morris, “addressing the world’s leading killer which is cardiovascular disease.” The BIOLIFE4D group is comprised of a team of preeminent researchers from different disciplines, with a mission Steven Morris says, “Dedicated to saving as many lives as possible, on a global basis.”
BIOLIFE4D has partnered with The Hechtman Group from the inception of the company. Morris shares, “The Hechtman Group handles our accounting needs, but the relationship is more strategic and deeper than that. They have played an important role for BIOLIFE4D from concept and start-up to effectively positioning our current operations to be efficient in the short term and to have a long-range vision and prepare us to handle our continued growth.” For Jim Hechtman, Managing Partner of The Hechtman Group, this long-range planning is critical, “BIOLIFE4D is a pioneer in advances in medical technology. We believe in the company and want to help them succeed long-term.”
We are proud to support BIOLIFE4D. To learn more visit: https://biolife4d.com/
Recently featured on ABC 7 Chicago News, learn how BIOLIFE4D is working to change the lives of heart patients through the development of a fully functioning patient-specific heart created using the patient’s own cells and 3D bioprinting. Click here to watch the full video